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Objective: The primary objective was to evaluate the effect of statin therapy/lipid lowering
therapy (LLT) on lipid proﬁle, in adults presenting with ﬁrst acute coronary event.
Methods and material: A multicentre, observational, prospective cohort study of lipid proﬁles
pre- and post-statin therapy/LLT, among adult patients with conﬁrmed diagnosis of ﬁrst
acute coronary event. The primary outcome measures were low-density lipoprotein choles-
terol (LDL-C) in mg/dl, high-density lipoprotein cholesterol (HDL-C) in mg/dl and triglycerides
(TG) in mg/dl at baseline and end of study (EOS, 12 weeks [mean: 13.5 weeks]).
Results: Totally 474 patients completed the study. Number of patients with any LDL-C
abnormality (LDL-C [all; LDL was abnormal, either alone or along with other lipid parame-
ter(s)]) decreased from 118 (24.9%) to 27 (5.7%), and for LDL-C (only; only the LDL was
abnormal), from 46 (9.7%) to 13 (2.7%), both from baseline to EOS. Of 118 patients with high
LDL-C (all) at baseline, 91 (77.1%) had reduction in LDL-C to <100 mg/dl, of which 54 (45.8%)
had LDL-C <70 mg/dl at EOS. The patients with LDL-C fraction abnormalities decreased,
while HDL-C abnormalities increased at EOS from baseline. No major difference was ob-
served at baseline and EOS in levels of TG (all [TG was abnormal, either alone or along with
other lipid parameter(s)]) and TG (only [only the TG was abnormal]). Six (1.3%) had seven
serious adverse events.
Conclusions: Though statin therapy is effective in lowering LDL-C, there still remains residual
dyslipidemia, which probably should be tackled with therapeutic and non-therapeutic
options.
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article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Several large trials have demonstrated the efﬁcacy of statins in
the primary prevention of cardiovascular events, including
ﬁrst acute major coronary event in adults with average
triglycerides (TG) and low-density lipoprotein-cholesterol
(LDL-C) and below average high-density lipoprotein-choles-
terol (HDL-C) levels.1–4 Further, trials on statin therapy such as
Scandinavian Simvastatin Survival Study (4S)5 and Cholesterol
and Recurrent Events Trial (CARE)6 also established their role
in reducing coronary events such as stroke risk, fatal coronary
artery disease (CAD) and nonfatal myocardial infarction (MI).
For secondary prevention of acute coronary events, high levels
of LDL-C, carotid artery remodeling, morbid obesity and low
levels of HDL-C are important prognostic indicators to evaluate
the efﬁcacy of aggressive lipid therapy strategies.7
The prevalence of dyslipidemia is increased in diabetic
patients, which contributes to the higher incidence of
cardiovascular diseases (CVDs), resulting in higher morbidity
and mortality.8 The American Diabetes Association recom-
mends the use of statins by diabetic patients with overt CVD
and by patients without CVD who are older than 40 years of age
and have one or more CVD risk factors, regardless of baseline
lipid levels.9
At present, statins are the gold-standard treatment options
for lowering LDL-C. Additionally statins are also known for
their ability to reduce the risk of cardiovascular events and
their excellent safety proﬁle.10–12 Besides LDL-C, other lipid
parameters, such as high TG13,14 and low HDL-C levels15,16 also
play a role in the causation and progression of coronary heart
disease (CHD).
One of the Cholesterol Treatment Trialists' Collaboration
(CCT) meta-analyses states that statin therapy can safely
reduce the 5-year incidence of major coronary events,
coronary revascularization, and stroke by about one ﬁfth per
mmol/L reduction in LDL cholesterol, largely irrespective of the
initial lipid proﬁle or other presenting characteristics.17
Management of lipid parameters beyond LDL-C may
require additional therapeutic or non-therapeutic options to
statin therapy, to likely beneﬁt the patients with residual
risks.18,19 In clinical practice, there is scarce information about
the extent to which CHD patients on lipid therapy achieve
control of HDL-C, LDL-C, and TG. Further, there is paucity of
data regarding occurrence of cardiovascular events among
patients with mixed dyslipidemia (at least 2 lipid abnormali-
ties) compared to patients with LDL-C abnormalities alone.
There is also a lack of understanding in the use of
comprehensive lipid management therapies to target dyslipi-
demia beyond LDL-C as a secondary prevention measure
subsequent to a CHD event.
In India, there is a wide gap in translation of evidence to
practice. Though there is evidence20 to suggest that in patients
with diabetes, low HDL-C levels are stronger predictor of
mortality from CHD than LDL-C, further quantiﬁcation of
protocol based treatment regimen as well as residual
abnormality and risk has never been studied.
The primary objective of our observational study was to
evaluate the effect of statin therapy/LLT on lipid proﬁle, in
Indian adults presenting with ﬁrst acute coronary event. Theprevalence of mixed dyslipidemia, the need to address low
HDL-C and/or high TG in addition to, or in the absence of high
LDL-C post statin therapy/LLT, and the various risk subgroups
(including individuals with prevalent diabetes mellitus) were
also assessed.
2. Materials and methods
2.1. Study design
We conducted a multicenter, observational, prospective
cohort study in 19 tertiary care centers of India in patients
with ﬁrst acute coronary event. The study was planned for 12
weeks from the onset of ﬁrst acute coronary event. However,
all patients who were on statin therapy/LLT (as per the
discretion of their respective investigators) for an average of
13.5 weeks were analyzed in this study. This was taken as the
end of study (EOS) period.
2.2. Setting
The study was initiated on 23rd April 2010 and was completed
at all the centers by 15th December 2012. The patients were
enrolled at the time of their ﬁrst acute coronary event
presentation (Index Date), information about demographics;
current medical treatment, family history and acute coronary
event were collected by interviewing the patients. Physical
examination was conducted of all the patients prior to
discharge. At baseline and EOS visits, investigations and lipid
assessments were performed. The study ﬂow chart is
presented in Fig. 1. The required study data was collected
and entered into a case record form (CRF). The ﬁnal protocol
and informed consent form (ICF) were reviewed and approved
by the Institutional Ethics Committees/Institutional Review
Boards, at each trial sites, participating in the study. Prior to
initiation of the study, a written informed consent was
obtained from the patients, who participated in this study.
Each participating tertiary care center with dedicated cardiac/
coronary care facility was responsible for recording and
maintaining the data in source documents in compliance
with the International Conference on Harmonization of
Technical Requirements for Registration of Pharmaceuticals
for Human Use (ICH) – Good Clinical Practice (GCP) and
institutional requirements for the protection of conﬁdentiality
of patients.
2.3. Study population
Men and women aged ≥35 years with a conﬁrmed diagnosis of
ﬁrst acute coronary event (STEMI [ST elevation myocardial
infarction]/NSTEMI [non-ST elevation myocardial infarction]/
unstable angina) were included in the study. Other inclusion
criteria were: access to medical records covering the entire
study period, potential to collect (8 h) fasting blood sample
within 24 h of onset for symptoms; considered for initiation/
maintenance/modiﬁcation of statin therapy before discharge
from hospital; availability of core data set and willing to
comply with the study requirements. Patients who were
already participating in a clinical trial or any other type of
Study Period
Initiation of Maintenance Statin Therapy/LLT
Index Date
(Initial Acute  Coronary Event) Foll ow-up Period*                                  Foll ow-up 
Pre Stati n Therapy/LLT:  Post Sta rt  of Sta tin Therapy/LLT Post Stati n Therapy/LL T:
Lipid Profile Meas urement Lipid Pr ofile Meas urement
Fig. 1 – Study flow chart. *12 weeks [Mean (SD) of 13.5 (1.8) weeks].
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otherwise failed to consent to interview; patients with known
inherited disorder of lipoprotein metabolism; and with history
of hypothyroidism, nephrotic syndrome, chronic alcoholism,
or Cushing's syndrome were excluded. Patients were discon-
tinued from the study if they experienced any major
cardiovascular event (fatal, non-fatal) during the follow-up
period e.g. MI, stroke, angina, transient ischemic attacks or
acute worsening of congestive heart failure or if they withdrew
informed consent.
2.4. Treatment
There was no protocol speciﬁed treatment or intervention that
was given to the patient, however as per the eligibility, the trial
patients were considered for initiation/maintenance/modiﬁ-
cation of statin therapy before discharge from hospital. Statin
therapies prescribed in all the trial sites as per the institutional
regimen included atorvastatin (10, 20, 40, 80 mg), rosuvastatin
(10, 20 and 40 mg), simvastatin (40 mg) and other LLT, such as
fenoﬁbric acid/fenoﬁbrate (145 and 160 mg).
2.5. End-points
The primary end-points described the lipid proﬁle and
quantiﬁed the inadequacy/under treatment with statins
among all patients and various risk subgroups (including
individuals with prevalent diabetes mellitus) experiencing
their ﬁrst acute coronary event. The secondary end-points
were the prevalence of mixed dyslipidemia and the need to
address low HDL-C and/or high TG in addition to, or in the
absence of high LDL-C, at EOS, post statin therapy/LLT
subsequent to the ﬁrst acute coronary event among all
patients, as well as to assess the risk subgroups (including
individuals with prevalent diabetes mellitus).
2.6. Statistical methods
The study was not based on a hypothesized effect size; hence,
a formal estimation of statistical power was not applicable. All
statistical analyses were performed using SAS® for Windows
Version 9.2. The p ≤ 0.05 was considered as statistically
signiﬁcant. The full analysis set (FAS) included all thosepatients treated with statin therapy/LLT and who completed
the study as per protocol. The primary and secondary efﬁcacy
analyses were performed on patients in FAS population. The
safety population (SAF) included all enrolled patients who
satisﬁed all inclusion and exclusion criteria. The analysis of all
safety end-points was based on SAF. Safety analysis included
the analysis of vital signs (systolic blood pressure [SBP]
and diastolic blood pressure [DBP], pulse rate [beats/min]
and respiratory rate [breaths/min]), and laboratory variables
(LDL-C, HDL-C, TG, lipoprotein [a], apoprotein A1, apoprotein B,
hs-CRP and random blood glucose [all in mg/dl] and HbA1c
[%]). Blood pressure was measured minimum of 2 times and an
average of SBP and DBP was used; if measured more than
twice. Multiple logistic analyses were used to obtain associa-
tion between risk factors and for sub-group analysis in diabetic
and non-diabetic patients. Descriptive statistics of observed
values and changes from baseline were provided for all above
vital signs and laboratory parameters. No formal inferential
statistical analysis was performed for these parameters.
3. Results
A total of 635 patients were enrolled in the study, of which 514
(80.9%) had completed data. Of these 514 patients with
completed data, 40 (6.3%) patients discontinued from the
study. Four hundred and seventy four (74.6%) patients
completed the study and were included in the FAS dataset.
All the 635 enrolled patients were included in the SAF dataset.
A summary of patient's demographic characteristics is as
shown in Table 1. The mean (SD) age of the patients was 54.2
(10.60) years and the mean (SD) BMI (kg/m2) was 25.56 (3.649).
Of 474 patients who completed the study, 80.2% were male
patients (n = 380) whereas female patients comprising only
19.8% (n = 94), with majority of female patients being in post-
menopausal phase (83/94 [88.3%]). Among the completers, 195
(41.1%) patients had history of hypertension and 137 (28.9%)
patients had history of diabetes mellitus. At baseline, 453
(95.6%) patients were not on statin therapy and only 21 (4.4%)
patients were taking statins, for a median duration of one
week, at the time of enrolment (there was an outlier, one
subject who was on statin therapy since 381 weeks). All
the patients at baseline (n = 635) as well as at EOS (n = 474)
Table 1 – Summary of patient demographic characteristics.
Variable Statistics Total
Number of patients enrolled n 635
Number of patients who completed the study n (%) 474 (74.6)a
Number of patients who discontinued from the study n (%) 161 (25.4)a
Primary reason for discontinuation:
Patient not fulﬁlling selection criteria n (%) 1 (0.2)a
Clinical trial was terminated at this site n (%) 0 (0.0)a
Clinical trial was terminated by Sponsor n (%) 0 (0.0)a
Other reasons n (%) 160 (25.2)a
Number of patients in safety population (SAF) n (%) 635 (100.0)a
Number of patients in full analysis set (FAS) n (%) 474 (74.6)a
Data of patients who completed the study (n = 474)
Age (in years) Mean (SD) 54.2 (10.60)b
Gender: Female n (%) 94 (19.8)b
Gender: Male n (%) 380 (80.2)b
If female, menopausalc
Yes n (%) 83 (88.3)b
No n (%) 11 (11.7)b
Patients with hypertension n (%) 195 (41.1)b
Patients with diabetes mellitus n (%) 137 (28.9)b
Patients on statin therapy at baseline n (%) 21 (4.4)b
Duration on statin therapy (weeks)d Mean (SD) 21.5 (83.11)b
Patients not on statin therapy at baseline n (%) 453 (95.6)b
BMI (kg/m2) at baseline (n = 473) Mean (SD) 25.56 (3.649)
a Percentages were based on number of patients enrolled.
b Percentages were based on number of patients in full analysis set (FAS).
c Percentages were based on total number of female patients in FAS.
d Duration on statin therapy (weeks) = Date of first dose of statin therapy  Date of baseline visit.
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Adult Treatment Panel III (NCEP ATP III) high risk group.
The details of prevalence of dyslipidemia at baseline and
at EOS are presented in Table 2. The number of patients with
LDL-C (all) abnormality decreased from 24.9% (n = 118) at visitTable 2 – Prevalence of dyslipidemia (FAS population).
Lipid abnormality 
At baseline,
n (%)
LDL-C (all) 118 (24.9) 
HDL-C 234 (49.4) 
TG 83 (17.5) 
LDL-C (only) 46 (9.7) 
HDL-C only 133 (28.1) 
TG only 19 (4.0) 
LDL-C (all) + HDL-C but not TG 44 (9.3) 
LDL-C (all) + TG but not HDL-C 7 (1.5) 
HDL-C + TG but not LDL-C (all) 36 (7.6) 
HDL-C + TG + LDL-C (all) 21 (4.4) 
Number (%) of patients with mixed dyslipidemia 108 (22.8) 
Percentages were based on number of patients in full analysis set (FAS).
a Indicates percentages were based on number of LDL-C (all) patients at 
Mixed dyslipidemia was deﬁned as the presence of at least 2 abnormal l
(all): LDL/TG was abnormal, either alone or along with other lipid param
(only): only the LDL/TG was abnormal.
Elevated LDL-C: ≥RF (risk factors) or CVD or DM: LDL ≥ 100 mg/dl (i.e. 2.6 m
≥2RF: LDLv130 mg/dl (i.e. 3.3 mmol/L).
<2RF: LDL ≥ 160 mg/dl (i.e. 4.1 mmol/L).
Low HDL-C: HDL < 40 mg/dl (1.0 mmol/L) for men and HDL-C < 50 mg/dl (
Elevated TG: TG ≥ 200 mg/dl (i.e. 2.3 mmol/L); however normal TG is <1501 to 5.7% (n = 27) at EOS. Similar trend was also seen in patients
with LDL-C (only) abnormality wherein the values decreased
from 9.7% (n = 46) at baseline to 2.7% (n = 13) at EOS. However,
an inverse trend was observed in the number of patients with
HDL fraction abnormality, namely HDL-C (all), HDL-C (only),Total (n = 474)
At EOS,
n (%)
At EOS LDL < 70,
n (%)
At EOS LDL < 100,
n (%)
27 (5.7) 54 (45.8)a 91 (77.1)a
258 (54.4)
81 (17.1)
13 (2.7)
192 (40.5)
18 (3.8)
6 (1.3)
3 (0.6)
55 (11.6)
5 (1.1)
69 (14.6)
baseline.
ipid values.
eter(s).
mol/L).
1.3 mmol/L) for women.
 mg/dl (i.e. 1.7 mmol/L).
Table 3 – Summary of lipid lowering agents by dose (FAS population).
Lipid lowering agent During hospitalization n (%)a Total (n = 474) At EOS n (%)a
Statin
Atorvastatin 10 mg 15 (3.2) 16 (3.4)
Atorvastatin 20 mg 49 (10.3) 73 (15.4)
Atorvastatin 40 mg 235 (49.6) 242 (51.1)
Atorvastatin 80 mg 157 (33.1) 146 (30.8)
Rosuvastatin 10 mg 8 (1.7) 21 (4.4)
Rosuvastatin 20 mg 6 (1.3) 12 (2.5)
Rosuvastatin 40 mg 9 (1.9) 9 (1.9)
Simvastatin 40 mg 1 (0.2) 0
Other
Fenoﬁbrate 160 mg 2 (0.4) 2 (0.4)
Fenoﬁbric acid 145 mg 1 (0.2) 1 (0.2)
Percentages are based on number of patients in full analysis set (FAS).
a One patient has been counted at more than one instance in statin or other.
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patients increased at EOS as compared with baseline (234
[49.4%] to 258 [54.4%], 133 [28.1%] to 192 [40.5%] and 36 [7.6%] to
55 [11.6%], respectively). No major difference was observed
between baseline and EOS in number of patients with
abnormal TG fraction, namely TG (all) and TG (only)
abnormality. The total number of patients with mixed
dyslipidemia decreased at EOS as compared with baseline
(108 [22.8%] to 69 [14.6%]).
At baseline, a majority of patients (330 [69.6%]) were non-
smokers, however, they increased in number at EOS (354
[74.7%]). The median of average number of packs smoked per
day by the smokers (current and former) at baseline and EOS
was one, for a median duration of 15 years. At baseline, a
majority of patients (390 [82.3%]) did not consume alcohol, and
they increased in number at EOS (416 [87.8%]). Hence, majority
of the patients were non-smokers and did not consume
alcohol. A total of 273 (57.6%) patients had at least one medical
history at baseline.
There were a total of 45 (9.5%) patients with at least one
family history, of which 28 (5.9%) had family history of
diabetes and 22 (4.6%) had family history of MI or sudden death
either before the age of 55 years for males, or 65 years for
females. A summary of lipid lowering agents by dose is
provided in Table 3. Atorvastatin 40 mg had been prescribed to
a majority of patients during hospitalization (n = 235). The
same trend was also seen at EOS i.e. at week 12 (n = 242),
followed by Atorvastatin 80 mg which was prescribed to 157
patients at visit 1 and 146 patients at EOS, and Atorvastatin
20 mg had been prescribed to 49 patients at visit 1 and 73
patients at EOS. Rosuvastatin (10 mg, 20 mg and 40 mg),
simvastatin 40 mg and fenoﬁbric acid (145 and 160 mg) was
prescribed to a very small number of patients.
A table of multivariate analysis presenting association
between dyslipidemia, statin therapy/LLT and patient char-
acteristics is provided in Table 4. Elevated LDL-C and TG, and
low HDL-C had statistically signiﬁcant associations (p < 0.05)
with patient characteristics such as age, diabetes, cigarette
smoking, BMI, gender, and hypertension at baseline, and with
hypertension and age at EOS. The subgroup analysis of 137
diabetic patients and 336 non-diabetic patients presenting
association between dyslipidemia, statin therapy/LLT and
patient characteristics are as shown in Table 5. In diabeticpatients, low HDL-C and elevated TG had statistically signiﬁ-
cant associations (p < 0.05) with cigarette smoking, BMI,
gender at baseline, and with cigarette smoking and hyperten-
sion at EOS, for elevated TG. In non-diabetic patients, elevated
LDL-C, low HDL-C and elevated TG had statistically signiﬁcant
associations (p ≤ 0.05) with age, cigarette smoking, BMI,
gender, and hypertension at baseline, and with age at EOS,
for low LDL-C and elevated TG. The median change from
baseline to visit 2 (EOS) was 35 in TC (mg/dl), 33 in measured
LDL-C (mg/dl), 1 in HDL-C (mg/dl), 3 in TG (mg/dl), 4 in
lipoprotein (a) (NMOL/L), 7 in apoprotein A1 (mg/dl), 7.55 in
hs-CRP (mg/L), and no change in HbA1c (%). The median
change from baseline to visit 2 values suggests improvement
in the laboratory values of TC, LDL-C and hs-CRP. However,
there was marginal to no change or deterioration observed at
EOS in the values of HDL-C, TG, lipoprotein (a), apoprotein A1
and HbA1c. Serious adverse events (SAEs) by system organ
class (SOC) and preferred term (PT) are presented in Table 6. Of
474 patients, 6 (1.3%) patients had a total of seven SAEs. Of the
seven SAEs by SOC, 5 (1.1%) belonged to cardiac disorders, 1
(0.2%) to infections and infestations, and 1 (0.2%) to nervous
system disorder. No major change from baseline to EOS was
observed in any of the median values of the vital signs. The
physical examination ﬁndings were similar for all the
parameters for both baseline and EOS visits. All the patients
in SAF had at least one clinical information data, however,
none had occurrence of any major event during the follow-up
period. All the patients (474) had taken statin therapy/LLT
during the follow-up and had taken other concomitant
medication at discharge.
4. Discussion
In the current observational study, statin therapy/LLT was
found to be effective in reducing the number of patients with
primarily abnormal LDL-C fraction and mixed dyslipidemia.
Our ﬁndings are consistent with the Prospective Cardiovascu-
lar Münster (PROCAM, 2010) study, which showed that many
MI survivors had high TG and/or low HDL-C versus matched
controls, and CV risk associated with the dyslipidemic proﬁle
was higher despite low LDL-C levels.21 High LDL-C had
statistically signiﬁcant association with age ( p = 0.0078),
Table 4 – Multivariate analysis to obtain association between dyslipidemia, statin therapy/LLT and patient characteristics
(FAS population).
Dependent variable Variable Total (n = 474)
At baseline At EOS
Adjusted ORa 95% CIa p-Valuea Adjusted ORa 95% CIa p-Valuea
Elevated LDL-C Age (years) 2.1670 1.1955–3.9279 0.0078 2.8770 0.8163–10.1401 0.1205
BMI (kg/m2) 0.9200 0.8166–1.0365 0.1693
Prior cerebro-vascular
disease
4.0801 0.3522–47.2679 0.2269
Diabetes 2.1939 1.3674–3.5198 0.0002 1.9057 0.8184–4.4376 0.1433
Gender 0.5616 0.2908–1.0847 0.1225 2.3737 0.8648–6.5152 0.0771
Hypertension 1.3681 0.8663–2.1605 0.1735 2.6593 1.1068–6.3898 0.0059
Cigarette smoking status 1.7581 1.0778–2.8679 0.0049 2.6482 1.0091–6.9494 0.1515
Low HDL-C Age (years) 0.7816 0.5017–1.2175 0.2753 0.6256 0.4041–0.9687 0.0200
BMI (kg/m2) 1.0643 1.0098–1.1217 0.0178
Diabetes 1.7492 1.1522–2.6557 0.0091
Gender 2.3700 1.4491–3.8761 0.0000 1.3436 0.8400–2.1489 0.2168
Elevated TG Age (years) 0.4954 0.2957–0.8300 0.0078
BMI (kg/m2) 1.0933 1.0244–1.1668 0.0091 0.9551 0.8930–1.0216 0.1797
Hypertension 1.8516 1.1236–3.0515 0.0148
Cigarette Smoking Status 2.2800 1.3586–3.8265 0.0049
a Was obtained by the methods of multiple logistic analysis.
EOS, end of study; FAS, full analysis set; OR, odds ratio.
An OR is a measure of association between an exposure and an outcome.
Elevated LDL-C: ≥RF (risk factors) or CVD or DM: LDL ≥ 100 mg/dl (i.e. 2.6 mmol/L).
≥2RF: LDLv130 mg/dl (i.e. 3.3 mmol/L).
<2RF: LDL ≥ 160 mg/dl (i.e. 4.1 mmol/L).
Low HDL-C: HDL < 40 mg/dl (1.0 mmol/L) for men and HDL-C < 50 mg/dl (1.3 mmol/L) for women.
Elevated TG: TG ≥ 200 mg/dl (i.e. 2.3 mmol/L); however normal TG is <150 mg/dl (i.e. 1.7 mmol/L).
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The association of high LDL-C with age, diabetes, cigarette
smoking, and hypertension highlights the importance of
treating abnormal LDL-C levels in patients with such risk
factors. In diabetic patients the LDL-C levels increased with
hypertension. The LDL-C levels also increased with prior
cerebro-vascular disease. In non-diabetic patients, the associ-
ation of high LDL-C was statistically signiﬁcant with age,
hypertension and cigarette smoking prior to statin therapy but
the association was not statistically signiﬁcant post statin
therapy. Our ﬁndings are similar to a period prevalence study
in which it was observed that co-occurrence of diabetes
mellitus, hypertension, and high LDL-C mandates compre-
hensive disease management strategies.22 The EUROASPIRE IV
study reported that only one-ﬁfth of the patients on lipid-
lowering medication achieved the Joint European Societies
(JES) 2012 CVD prevention guidelines recommended LDL-C
lowering target of ≤1.8 mmol/L. The study concluded
that coronary patients require more intensive cholesterol
management.23
However, in non-diabetic patients, low HDL-C had no
statistical signiﬁcant association with BMI and gender (male
over female); and this association either remained unchanged
or decreased post statin therapy. High TG had statistically
signiﬁcant association (p < 0.05) with BMI ( p = 0.0091), hyper-
tension (p = 0.0148), and cigarette smoking (p = 0.0049) prior to
statin therapy. In diabetic patients, TG levels increased with
cigarette smoking and gender (male over female) both pre and
post statin therapy; marginally increased with BMI prior to
statin therapy and post statin therapy it either remainedunchanged or decrease. However, in non-diabetic patients,
high TG levels had statistically signiﬁcant association with
hypertension prior to therapy and no signiﬁcant association
with cigarette smoking. Post therapy the association either
remained unchanged or decreased. The ﬁndings of HDL-C and
TG abnormalities are similar to those of the Copenhagen male
study, which stated that high TG-low HDL-C were powerful
predictors of IHD besides isolated high LDL-C. That study
inferred that prevention of IHD should emphasize on inter-
ventions targeting at high TG-low HDL-C and not just manage
overall hypercholesterolemia.24 A study of 1800 adults in India
revealed a high incidence of dyslipidemia; the prevalence
being higher in males.25 It was found that high cholesterol and
high TG were more prominent in adults aged 31–40 years than
those under age 30. Another study investigating dyslipidemia
in Asian Indians residing in India showed that the overall
prevalence of dyslipidemia ranged from 10% to 73%. Speciﬁ-
cally, prevalence of hypercholesterolemia was 28% in urban
patients as compared to 22% in the rural patients.26 High TG,
low HDL-C and high LDL-C levels characterize typical lipid
proﬁle in the Indian population.
Our ﬁndings signify the need to treat high LDL-C as well as
low HDL-C and high TG in diabetic population with associated
risk factors such as hypertension, BMI and gender (male over
female). Published literature has also reported that lipid
abnormalities (high LDL-C, low HDL-C and high TG) frequently
accompany both hypertension and glucose intolerance in
diabetes and in the metabolic syndrome.27,28
Inclusion of other drugs in addition to statin therapy was
suggested by Cziraky et al. to promote the cost-effective
Table 5 – Subgroup analysis of diabetic and non-diabetic patients to obtain association between dyslipidemia, statin therapy/LLT and patient characteristics (FAS
population).
Diabetic patients Total (n = 137) Non-diabetic patients Total (n = 336)
Dependent
variable
Variable At baseline At EOS Dependent
variable
Variable At baseline At EOS
Adjusted
ORa
95% CIa p-Valuea Adjusted
ORa
95% CIa p-Valuea Adjusted
ORa
95% CIa p-Valuea Adjusted
ORa
95% CIa p-Valuea
High LDL-C Prior cerebro-
vascular
disease
3.7873 0.3261–43.9863 0.2567 High
LDL-C
Age (years) 2.5529 1.2191–5.3461 0.0083 2.2769 0.4919–10.5399 0.2503
Gender 0.5099 0.2124–1.2237 0.1370 BMI (kg/m2) 0.8515 0.7112–1.0196 0.0935
Hypertension 1.8308 0.8521–3.9335 0.2232 3.8425 0.8168–18.0768 0.0698 Gender 0.4487 0.1650–1.2198 0.1088
Low HDL-C Age (years) 0.4991 0.1762–1.4648 0.2378 0.5457 0.2149–1.3855 0.2112 Hypertension 2.4416 0.8106–7.3545 0.0921
Prior cerebro-
vascular
disease
0.2269 0.0178–2.8473 0.2188 Cigarette
Smoking
Status
1.7473 0.9837–3.1034 0.0119 1.7921 0.5888–5.4550 0.2991
Gender 4.3086 1.5818–11.3031 0.0015 Low
HDL-C
Age (years) 0.6108 0.3733–0.9995 0.0488
Hypertension 1.5222 0.7566–3.0624 0.2377 BMI (kg/m2) 1.0650 1.0030–1.1310 0.0383
High TG BMI (kg/m2) 1.1486 1.0163–1.2981 0.0090 Gender 1.9790 1.1118–3.5226 0.0154
Gender 2.7676 0.9024–8.4882 0.0686 4.0959 1.3278–12.6345 0.0481 High
TG
Age (years) 0.5182 0.2864–0.9376 0.0289
Cigarette
smoking
status
6.5219 2.1823–19.4911 0.0016 3.7366 1.0817–12.9077 0.0289 BMI (kg/m2) 1.0537 0.9732–1.1409 0.1955 0.9378 0.8663–1.0151 0.1103
Hypertension 1.9475 1.0645–3.5627 0.0249
Cigarette
smoking
status
1.6373 0.8813–3.0418 0.1720
n is number of diabetic patients & non-diabetic patients.
a Is obtained by the methods of multiple logistic analysis.
EOS, end of study; FAS, full analysis set; OR, odds ratio.
An OR is a measure of association between an exposure and an outcome.
Elevated LDL-C: ≥RF (risk factors) or CVD or DM: LDL ≥ 100 mg/dl (i.e. 2.6 mmol/L).
≥2RF: LDLv130 mg/dl (i.e. 3.3 mmol/L).
<2RF: LDL ≥ 160 mg/dl (i.e. 4.1 mmol/L).
Low HDL-C: HDL < 40 mg/dl (1.0 mmol/L) for men and HDL-C < 50 mg/dl (1.3 mmol/L) for women.
Elevated TG: TG ≥ 200 mg/dl (i.e. 2.3 mmol/L); however normal TG is <150 mg/dl (i.e. 1.7 mmol/L).
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Table 6 – Summary of patients with SAE by SOC and PT.
System organ class preferred term Total (n = 474)
n (%)
Number of patients with at least one serious AE 6 (1.3)
Cardiac disorders 5 (1.1)
Inferior MI 1 (0.2)
Myocardial infarction 3 (0.6)
Triple vessel disease 1 (0.2)
Infections and infestations 1 (0.2)
Gastroenteritis 1 (0.2)
Nervous system disorder 1 (0.2)
Sensory disturbance 1 (0.2)
Percentages are based on the number of patients in full analysis set
(FAS) in respective visit. Serious adverse events (SAE); System
organ class (SOC) and preferred terms (PTs) are coded using the
MedDRA version 15.0 dictionary. If a patient experienced more
than one episode of an adverse event (AE), the patient is counted
once for that event. If a patient had more than one AE within a
SOC, the patient is counted once for each PT and once in that SOC.
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 6 4 6 – 6 5 4 653achievement of optimum lipid levels in several at-risk
patients.18 A similar study conducted in France29 demon-
strated that a signiﬁcant proportion of dyslipidemic patients
at high CV risk did not achieve treatment goals even after
statin therapy. Though statin therapy alone is not sufﬁcient
for managing lipid parameters, a study by Larsen et al.
emphasized the need of statin therapy to prevent adverse
clinical events, major adverse cardiac events, major bleeding
unrelated to bypass surgery, and death. Absence of a
discharge statin prescription after STEMI was an independent
predictor of ischemic events including death in this study.30
In daily clinical practice, almost one-third of patients with a
history of coronary event have residual lipid risk including
LDL-C <100 mg/dl, low HDL-C and/or high TG, known as
residual lipid risk.31 Though statin therapy is effective, a
substantial proportion of patients still remain with residual
dyslipidemia. Several large studies (CEPHEUS, DYSIS) have
reported the need for comprehensive and intensive surveil-
lance, awareness and treatment regimen for lowering lipids,
especially in patients at a high risk for CVD.32,33
This observational cohort study had a few inherent
limitations. The study design itself could be associated
with introduction of bias at different stages. The other biases
were sampling and effect size, which were not taken into
consideration. Also, observation was not restricted to statin
therapy alone, but other LLT were also observed and assessed.
5. Conclusion
In conclusion, management of lipid parameters beyond LDL-C
would require additional therapeutic and non-therapeutic
options to statin therapy/LLT, to likely beneﬁt the patients
with residual risks. The scope of comprehensive lipid
management therapies may also include reducing the residual
cardiovascular risks associated with low HDL-C levels and high
TG levels. Future research directed toward comprehensive
drug therapy regimen for the management of overall lipid
abnormalities, in primary and secondary prevention of
cardiovascular events is suggested.Key messages:
(1) In our study, statin therapy/LLT was found to be
effective in reducing the number of patients with
primarily abnormal LDL-C fraction and mixed dysli-
pidemia. But statin therapy/LLT was not effective in
managing HDL fraction, lipoprotein (a) and TG
abnormalities.
(2) Management of lipid parameters beyond LDL-C
would require additional therapeutic and non-thera-
peutic options to statin therapy/LLT, to likely beneﬁt
the patients with residual risks.
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